Nimodipine treatment of an adolescent with ultradian cycling bipolar affective illness.
This is a single case report of an open trial of nimodipine, a dihydropyridine-type calcium antagonist, in the treatment of a 13-year-old boy with refractory, ultradian rapid cycling, bipolar disorder type I. Prior clinical trials with calcium channel blockers in adults with ultrarapid cycling affective disorder supported an empirical trial of nimodipine for treatment of ultradian rapid cycling in this adolescent. Severity of mania and depression were rated before and after nimodipine therapy. A marked decrease in rapid, repeated, and significant mood changes was clinically observed and measured by standardized scales after 9 days of nimodipine 180 mg daily. No adverse effects were noticed. Remission persisted with continued treatment at 36-month follow-up. Medication response was partially attributed to adjunctive therapy with levothyroxine. Implications of treatment benefit are discussed in the context of novel pharmacotherapies for refractory bipolar disorder. These findings are preliminary and do not provide sufficient basis to recommend nimodipine as the treatment of choice in adolescents with ultradian cycling bipolar disorder, but suggest that controlled studies may be indicated.
Davanzo
P A
PA
Department of Psychiatry and Behavioral Sciences, University of California, Los Angeles, USA.
Krah
N
N
Kleiner
J
J
McCracken
J
J
D000204:Activity Cycles / Q000502:physiology; D000293:Adolescent; D018692:Antimanic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009553:Nimodipine / Q000627:therapeutic use*; D013960:Thyroid Function Tests
D018692:Antimanic Agents; D002121:Calcium Channel Blockers; D009553:Nimodipine